{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:12Z","timestamp":1793382972304,"version":"4.5.0"},"reference-count":103,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gilead Sciences Spain"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2023,1,2]]},"DOI":"10.1080\/14787210.2023.2149490","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T18:42:17Z","timestamp":1668796937000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of the design and methodology of Phase 3 clinical trials of bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature"],"prefix":"10.1080","volume":"21","author":[{"given":"Santiago","family":"Grau","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain"},{"name":"CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Olalla","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Costa Del Sol, Marbella, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C","family":"Alcal\u00e1","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Castro","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Rubio-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Health Value, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rubio-Terr\u00e9s","sequence":"additional","affiliation":[{"name":"Health Value, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"#cr-split#-cit0002.1","unstructured":"Unidad de Vigilancia de VIH, Conductas de R. Mortalidad por VIH y sida en Espa\u00f1a, a\u00f1o 2017. Evoluci\u00f3n 1981-2017. Centro Nacional de Epidemiolog\u00eda, Instituto de Salud Carlos III\/ Plan Nacional sobre el Sida, Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n. Madrid"},{"key":"#cr-split#-cit0002.2","unstructured":"2019. Available from: https:\/\/www.mscbs.gob.es\/ca\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/vigilancia\/doc\/MortalidadXVIH2017.pdf (cited 2020 May 29). \u2022 Mortality due to HIV and AIDS in Spain. Evolution 1981-2017."},{"key":"cit0003","unstructured":"Direcci\u00f3n General de Salud P\u00fablica. Calidad e Innovaci\u00f3n. Informe de evaluaci\u00f3n. Plan estrat\u00e9gico de prevenci\u00f3n y control del VIH e ITS de 2013-2016. Plan Nacional del SIDA. 2018. Available from: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/sida\/planesEstrat\/informeEvaluacion_VDweb_12Dicbre18.pdf (cited 2019 Jun 30). \u2022 Strategic plan for the prevention and control of HIV in Spain (2013-2016)."},{"key":"cit0004","first-page":"11","volume":"8","author":"D\u00edaz A","year":"2020","journal-title":"Rev Multidisciplinar del Sida"},{"key":"cit0005","unstructured":"Unidad de Vigilancia de VIH, Conductas de R. Mortalidad por VIH y sida en Espa\u00f1a, a\u00f1o 2017. Evoluci\u00f3n 1981-2017. Centro Nacional de Epidemiolog\u00eda, Instituto de Salud Carlos III\/ Plan Nacional sobre el Sida, Direcci\u00f3n General de Salud P\u00fablica, Calidad e Innovaci\u00f3n. Madrid; 2019."},{"key":"cit0006","volume-title":"T\u00e9rminos relacionados con el VIH\/SISA","author":"Glosario de Infosida","year":"2021","edition":"9"},{"key":"cit0007","unstructured":"Panel de Expertos de GeSIDA y Divisi\u00f3n de control de VIH, ITS, Hepatitis virales y Tuberculosis. Plan Nacional sobre el SIDA. Documento de consenso de GeSIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (update 2022). GeSIDA\/Ministerio de Sanidad. Available from: https:\/\/gesida-seimc.org\/wp-content\/uploads\/2022\/05\/GuiaGeSIDAPlanNacionalSobreElSidaRespectoAlTratamientoAntirretroviralEnAdultosInfectadosPorElVirusDeLaInmunodeficienciaHumanaActualizacionEnero2022.pdf (cited 2022 May 30). \u2022\u2022 GeSIDA Consensus Document\/National Plan on AIDS."},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0517-1"},{"key":"cit0010","unstructured":"Biktarvy 50 mg\/200 mg\/25 mg film-coated tablets. Summary of Product Specifications, 2018 Jun 21. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/biktarvy-epar-product-information_en.pdf (cited 2021 Nov 19)."},{"key":"cit0011","unstructured":"Biktarvy. Assessment report. EMA\/293559\/2018. European Medicines Agency, 2018 Apr 26. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/biktarvy-epar-public-assessment-report_en.pdf (cited 2021 Nov 19). \u2022 EMA Assessment Report."},{"key":"cit0012","unstructured":"Dovato 50 mg\/300 mg film-coated tablets. Summary of product specifications, Cited 2019 Jul 1. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dovato-epar-product-information_en.pdf (cited 2021 Nov 19). \u2022 EMA Assessment Report."},{"key":"cit0013","unstructured":"Dovato. Assessment report. EMA\/267082\/2019. European Medicines Agency, 2019 Apr 26. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/dovato-epar-public-assessment-report_en.pdf (cited 2021 Nov 19). \u2022 EMA Assessment Report."},{"key":"cit0014","unstructured":"Juluca 50 mg\/25 mg film-coated tablets. Summary of Product Specifications, 2018 May 16. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/juluca-epar-product-information_en.pdf (cited 19 November 2021). \u2022 EMA Assessment Report."},{"key":"cit0015","unstructured":"Juluca. Assessment report. EMA\/243517\/2018. European Medicines Agency, 2018 Mar 26. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/juluca-epar-public-assessment-report_en.pdf (cited 2021 Nov 19). \u2022 EMA Assessment Report."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.2174\/157488709788186021"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002137"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30099-0"},{"key":"cit0020","unstructured":"CADTH. Clinical Review Report. Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (B\/FTC\/TAF) (Biktarvy). October 2018\/Canadian drug expert committee recommendation. Dolutegravir\/Rilpivirine (Juluca \u2014 ViiV Healthcare). Version 1.0. June, 2018."},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1560423"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00449-z"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30077-3"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"issue":"6","key":"cit0027","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink HJ","year":"2019","journal-title":"Lancet HIV"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002285"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002302"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz511"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13050"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12675"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1887135"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11050809"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0276"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1878"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"cit0039","volume-title":"Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment -na\u00efve adults with HIV-1 infection- 3 -year results from the GEMINI studies","author":"Cahn P","year":"2020"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003070"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa988"},{"issue":"7","key":"cit0042","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina JM","year":"2018","journal-title":"Lancet HIV"},{"issue":"7","key":"cit0043","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar ES","year":"2018","journal-title":"Lancet HIV"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00419-5"},{"key":"cit0045","first-page":"68","volume":"19","author":"Reynes J","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz009"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016813"},{"key":"cit0048","volume-title":"CROI 2020","author":"Gagliardini R"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105893"},{"key":"cit0050","first-page":"5923256","volume":"2020","author":"Ward D","year":"2020","journal-title":"AIDS Res Treat"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164753"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12506"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018761600"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001725"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1177\/2325958218760847"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017728294"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2019.1628460"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3270"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1177\/2325958218821657"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211038504"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0041"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018758432"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1417984"},{"key":"cit0065","unstructured":"Clinical review report: dolutegravir\/Rilpivirine (Juluca): (ViiV Healthcare): indication: as a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL). [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun. PMID: 30645063."},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S140767"},{"key":"cit0067","first-page":"215","volume":"10","author":"Dowers E","year":"2018","journal-title":"HIV AIDS (Auckl)"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019831674"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.08.010"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30149-3"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002449"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30015-7"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05850-0"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054821"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.603068"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-017-0093-8"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13146"},{"key":"cit0079","volume-title":"M\u00e9todos de investigaci\u00f3n aplicados a la atenci\u00f3n primaria de salud","author":"Argim\u00f3n JM","year":"1991"},{"issue":"8","key":"cit0080","first-page":"303","volume":"107","author":"Rubio Terr\u00e9s C","year":"1996","journal-title":"Med Clin (Barc)"},{"key":"cit0081","unstructured":"Note for guidance on statistical principles for clinical trials (CPMP\/ICH\/363\/96). European Medicines Agency (EMEA). September, 1998. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf (cited 2021 Jun 02)."},{"key":"cit0082","volume-title":"Dise\u00f1o de la investigaci\u00f3n cl\u00ednica. Un enfoque epidemiol\u00f3gico","author":"Hulley SB","year":"1993"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.01.035"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002699"},{"key":"cit0085","volume-title":"Clinical trials. Issues and approaches","author":"Shapiro SH","year":"1983"},{"key":"cit0086","volume-title":"Fundamentals of clinical trials","author":"Friedman LM","year":"1985"},{"key":"cit0087","first-page":"11","volume-title":"Metodolog\u00eda del ensayo cl\u00ednico","author":"De Abajo FJ","year":"1991"},{"issue":"20","key":"cit0088","first-page":"780","volume":"100","author":"Sacrist\u00e1n JA","year":"1993","journal-title":"Med Clin (Barc)"},{"key":"cit0089","volume-title":"Clinical epidemiology. A basic science for clinical medicine","author":"Sackett DL","year":"1985"},{"key":"cit0090","volume-title":"Evidence-based medicine: how to practice and teach EBM","author":"Sacket DL","year":"1997"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.025833"},{"key":"cit0092","unstructured":"Panel de Expertos de GeSIDA y Plan Nacional sobre el SIDA. Documento de consenso de GeSIDA\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (draft update 2022). GeSIDA\/Ministerio de Sanidad, 2022."},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv149"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.20000103"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2017-110798"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2016-110401"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy113"},{"key":"cit0099","volume-title":"Reviews in Antiviral Therapy & Infectious Diseases 2, 2021, presented at European Meeting on HIV & Hepatitis","author":"Santoro MM","year":"2021"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249515"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2021.01068"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14787210.2023.2149490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T07:16:07Z","timestamp":1673594167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14787210.2023.2149490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,2]]}},"alternative-id":["10.1080\/14787210.2023.2149490"],"URL":"https:\/\/doi.org\/10.1080\/14787210.2023.2149490","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}